Makoto Odaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Makoto Odaka has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Hisatoshi Asano
Department of Surgery, Jikei University School of Medicine, Tokyo, Japan
17 shared publications- Toshiaki Morikawa
Division of Chest Diseases; Department of Surgery, Jikei University School of Medicine, Tokyo, Japan
17 shared publications Takamasa Shibasaki
Department of Surgery, Jikei University School of Medicine, Tokyo, Japan
11 shared publications- Makoto Yamashita
Department of Chemistry, School of Science, Institute of Science Tokyo, 2-12-1-E1-2 Ookayama, Meguro-ku, Tokyo 152-8551, Japan
10 shared publications Toshiaki Morikawa
Department of Surgery, Jikei University School of Medicine, Tokyo, Japan
8 shared publicationsHideki Matsudaira
Department of Surgery, Jikei University School of Medicine, Tokyo, Japan
6 shared publications
Latest Publications
- 1 August 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (8) , 4985-4993
Impact of the introduction of thoracoscopic lobectomy for non-small cell lung cancer: a propensity score-matched analysis
Background: The present study evaluated the impact of the introduction of thoracoscopic lung lobectomy (TL) for non-small cell lung cancer at our institution. Methods: This study retrospectively compared surgical and oncological outcomes in the period before and after the introduction of TL for non-small cell lung cancer. Propensity score-matched analysis was performed with respect to baseline patient variables and tumor characteristics. Results: Patients were divided into two groups: those who underwent lung lobectomy in the period before (BI group, n=261) and after (AI group, n=261) the introduction of TL. The proportion of TLs at our institution increased from 1.3% in the BI group to 93% in the AI group. The AI group experienced a longer duration of surgery, lesser intraoperative blood loss, and a significantly shorter postoperative hospital stay (POHS). There were no significant differences in postoperative complications between the two groups. The median follow-up period was 50 months in both groups. No significant differences were observed between the BI and AI groups with respect to 5-year overall survival (OS) (76.1% and 71.7%, respectively; P=0.1973) and disease-free survival (DFS) (67.6% and 66.1%, respectively; P=0.4071). On multivariate analysis, pathological N1–2 status was an independent predictor of survival. AI group and TL showed no independent association with survival. Conclusions: The introduction of TL represented a positive change at our institution owing to decreased invasiveness and oncological equivalence of the surgical treatment for non-small cell lung cancer.
- 1 August 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (8) , 4985-4993
Impact of the introduction of thoracoscopic lobectomy for non-small cell lung cancer: a propensity score-matched analysis
Background: The present study evaluated the impact of the introduction of thoracoscopic lung lobectomy (TL) for non-small cell lung cancer at our institution. Methods: This study retrospectively compared surgical and oncological outcomes in the period before and after the introduction of TL for non-small cell lung cancer. Propensity score-matched analysis was performed with respect to baseline patient variables and tumor characteristics. Results: Patients were divided into two groups: those who underwent lung lobectomy in the period before (BI group, n=261) and after (AI group, n=261) the introduction of TL. The proportion of TLs at our institution increased from 1.3% in the BI group to 93% in the AI group. The AI group experienced a longer duration of surgery, lesser intraoperative blood loss, and a significantly shorter postoperative hospital stay (POHS). There were no significant differences in postoperative complications between the two groups. The median follow-up period was 50 months in both groups. No significant differences were observed between the BI and AI groups with respect to 5-year overall survival (OS) (76.1% and 71.7%, respectively; P=0.1973) and disease-free survival (DFS) (67.6% and 66.1%, respectively; P=0.4071). On multivariate analysis, pathological N1–2 status was an independent predictor of survival. AI group and TL showed no independent association with survival. Conclusions: The introduction of TL represented a positive change at our institution owing to decreased invasiveness and oncological equivalence of the surgical treatment for non-small cell lung cancer.
- 1 July 2018
- Published by AME Publishing Company in Journal of Visualized Surgery
- Vol. 4 (7) , 150
A novel intra-operative navigation system for resection of small lung nodules by video-assisted thoracoscopic surgery (VATS) using three-dimensional image construction in real time and on site with a tablet computer
Precise imaging modalities are necessary during pulmonary resection to assess nodules that are otherwise difficult to diagnose. Studies have demonstrated that partial lung resection can completely cure adenocarcinoma in situ and minimally invasive adenocarcinoma. The important considerations for partial lung resection are: (I) to accurately identify the location of a small tumor intraoperatively and (II) to ensure a sufficient resection margin and preserve the remaining lung function. Hence, precise detection of hardly palpable or invisible tumors is essential. Although some reports describe methods for marking tumor locations, these processes are both invasive and complicated. Here, we describe a novel intraoperative navigation system that easily feeds image information to the operator on-site and evaluated its feasibility in three cases of partial lung resection. Implementing the software developed by Amin Inc. allowed three-dimensional scaling, rotation, transparency display, and calculation of tumor volumes in real time using a tablet computer (TC) interfaced with a hand tracking and voice control device. The surgeon, assistant, and digital imaging assistant can preoperatively verify the image using a TC by simulating the virtual resection line and insertion angle of the endoscopic stapler. During surgery, the tumor was assessed with a thoracoscope in comparison with the constructed three-dimensional image. Partial resection was successfully performed and pathological excision margins were negative in all cases. Other than prolonged air leakage in one case, no other complications were encountered. This novel navigation system appears to be safe and effective for less invasive partial lung resection.
- 1 July 2018
- Published by AME Publishing Company in Journal of Visualized Surgery
- Vol. 4 (7) , 150
A novel intra-operative navigation system for resection of small lung nodules by video-assisted thoracoscopic surgery (VATS) using three-dimensional image construction in real time and on site with a tablet computer
Precise imaging modalities are necessary during pulmonary resection to assess nodules that are otherwise difficult to diagnose. Studies have demonstrated that partial lung resection can completely cure adenocarcinoma in situ and minimally invasive adenocarcinoma. The important considerations for partial lung resection are: (I) to accurately identify the location of a small tumor intraoperatively and (II) to ensure a sufficient resection margin and preserve the remaining lung function. Hence, precise detection of hardly palpable or invisible tumors is essential. Although some reports describe methods for marking tumor locations, these processes are both invasive and complicated. Here, we describe a novel intraoperative navigation system that easily feeds image information to the operator on-site and evaluated its feasibility in three cases of partial lung resection. Implementing the software developed by Amin Inc. allowed three-dimensional scaling, rotation, transparency display, and calculation of tumor volumes in real time using a tablet computer (TC) interfaced with a hand tracking and voice control device. The surgeon, assistant, and digital imaging assistant can preoperatively verify the image using a TC by simulating the virtual resection line and insertion angle of the endoscopic stapler. During surgery, the tumor was assessed with a thoracoscope in comparison with the constructed three-dimensional image. Partial resection was successfully performed and pathological excision margins were negative in all cases. Other than prolonged air leakage in one case, no other complications were encountered. This novel navigation system appears to be safe and effective for less invasive partial lung resection.
- 1 July 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 630
The digital imaging assistant is wearing the telephone headset, which is operated using the Leap Motion® system
- 1 July 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 630
The digital imaging assistant is wearing the telephone headset, which is operated using the Leap Motion® system
- 1 July 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 629
Monitor image obtained via a thoracoscope compared with the tablet computer (TC) image in the same view in the operating room
- 1 July 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 629
Monitor image obtained via a thoracoscope compared with the tablet computer (TC) image in the same view in the operating room
- Open Access
- 20 April 2018
- Published by Japan Lung Cancer Society in Haigan
- Vol. 58 (2) , 83-87
Surgical Outcomes of Thoracoscopic Metastasectomy for Head and Neck Cancer
目的.頭頚部癌の肺転移に対する胸腔鏡手術の治療成績を検討した.方法.2005年から2015年に頭頚部癌肺転移に対し肺切除術を施行した38例を対象とし,治療成績を調べた.結果.頭頚部癌の発生部位は咽頭癌17例,喉頭癌8例,舌癌8例であった.原発病変の病期は28例がstage III以上であった.頭頚部癌治療から2年以内に肺転移を来した症例が26例であった.頭頚部癌治療から肺転移発見までの期間(DFI)中央値は17か月(範囲:1~61か月)であった.全症例に対して胸腔鏡手術を行った.肺転移に対する肺切除術後の生存期間中央値は43か月(範囲:1~119か月),5年全生存率49.1%であった.DFI 17か月未満(p=0.0409),不完全切除(p<0.0003)症例で有意に予後不良であった.結論.頭頚部癌肺転移に対して完全切除が可能であれば,肺転移切除が予後を改善する可能性が示唆された.
- 20 April 2018
- Published by Japan Lung Cancer Society in Haigan
- Vol. 58 (2) , 83-87
Open AccessSurgical Outcomes of Thoracoscopic Metastasectomy for Head and Neck Cancer
目的.頭頚部癌の肺転移に対する胸腔鏡手術の治療成績を検討した.方法.2005年から2015年に頭頚部癌肺転移に対し肺切除術を施行した38例を対象とし,治療成績を調べた.結果.頭頚部癌の発生部位は咽頭癌17例,喉頭癌8例,舌癌8例であった.原発病変の病期は28例がstage III以上であった.頭頚部癌治療から2年以内に肺転移を来した症例が26例であった.頭頚部癌治療から肺転移発見までの期間(DFI)中央値は17か月(範囲:1~61か月)であった.全症例に対して胸腔鏡手術を行った.肺転移に対する肺切除術後の生存期間中央値は43か月(範囲:1~119か月),5年全生存率49.1%であった.DFI 17か月未満(p=0.0409),不完全切除(p<0.0003)症例で有意に予後不良であった.結論.頭頚部癌肺転移に対して完全切除が可能であれば,肺転移切除が予後を改善する可能性が示唆された.
- Open Access
- 2 June 2017
- Published by Springer Nature in Respiratory Research
- Vol. 18 (1) , 1-14
Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy
Pirfenidone (PFD) is an anti-fibrotic agent used to treat idiopathic pulmonary fibrosis (IPF), but its precise mechanism of action remains elusive. Accumulation of profibrotic myofibroblasts is a crucial process for fibrotic remodeling in IPF. Recent findings show participation of autophagy/mitophagy, part of the lysosomal degradation machinery, in IPF pathogenesis. Mitophagy has been implicated in myofibroblast differentiation through regulating mitochondrial reactive oxygen species (ROS)-mediated platelet-derived growth factor receptor (PDGFR) activation. In this study, the effect of PFD on autophagy/mitophagy activation in lung fibroblasts (LF) was evaluated, specifically the anti-fibrotic property of PFD for modulation of myofibroblast differentiation during insufficient mitophagy. Transforming growth factor-β (TGF-β)-induced or ATG5, ATG7, and PARK2 knockdown-mediated myofibroblast differentiation in LF were used for in vitro models. The anti-fibrotic role of PFD was examined in a bleomycin (BLM)-induced lung fibrosis model using PARK2 knockout (KO) mice. We found that PFD induced autophagy/mitophagy activation via enhanced PARK2 expression, which was partly involved in the inhibition of myofibroblast differentiation in the presence of TGF-β. PFD inhibited the myofibroblast differentiation induced by PARK2 knockdown by reducing mitochondrial ROS and PDGFR-PI3K-Akt activation. BLM-treated PARK2 KO mice demonstrated augmentation of lung fibrosis and oxidative modifications compared to those of BLM-treated wild type mice, which were efficiently attenuated by PFD. These results suggest that PFD induces PARK2-mediated mitophagy and also inhibits lung fibrosis development in the setting of insufficient mitophagy, which may at least partly explain the anti-fibrotic mechanisms of PFD for IPF treatment.
- 2 June 2017
- Published by Springer Nature in Respiratory Research
- Vol. 18 (1) , 1-14
Open AccessPirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy
Pirfenidone (PFD) is an anti-fibrotic agent used to treat idiopathic pulmonary fibrosis (IPF), but its precise mechanism of action remains elusive. Accumulation of profibrotic myofibroblasts is a crucial process for fibrotic remodeling in IPF. Recent findings show participation of autophagy/mitophagy, part of the lysosomal degradation machinery, in IPF pathogenesis. Mitophagy has been implicated in myofibroblast differentiation through regulating mitochondrial reactive oxygen species (ROS)-mediated platelet-derived growth factor receptor (PDGFR) activation. In this study, the effect of PFD on autophagy/mitophagy activation in lung fibroblasts (LF) was evaluated, specifically the anti-fibrotic property of PFD for modulation of myofibroblast differentiation during insufficient mitophagy. Transforming growth factor-β (TGF-β)-induced or ATG5, ATG7, and PARK2 knockdown-mediated myofibroblast differentiation in LF were used for in vitro models. The anti-fibrotic role of PFD was examined in a bleomycin (BLM)-induced lung fibrosis model using PARK2 knockout (KO) mice. We found that PFD induced autophagy/mitophagy activation via enhanced PARK2 expression, which was partly involved in the inhibition of myofibroblast differentiation in the presence of TGF-β. PFD inhibited the myofibroblast differentiation induced by PARK2 knockdown by reducing mitochondrial ROS and PDGFR-PI3K-Akt activation. BLM-treated PARK2 KO mice demonstrated augmentation of lung fibrosis and oxidative modifications compared to those of BLM-treated wild type mice, which were efficiently attenuated by PFD. These results suggest that PFD induces PARK2-mediated mitophagy and also inhibits lung fibrosis development in the setting of insufficient mitophagy, which may at least partly explain the anti-fibrotic mechanisms of PFD for IPF treatment.
- 11 April 2017
- Published by AME Publishing Company in Journal of Visualized Surgery
- Vol. 3 (4) , 54
Surgical and oncological outcomes of thoracoscopic thymectomy for thymoma
Thymoma remains the most common primary anterior mediastinal neoplasm. Surgical resection remains central to the treatment of thymoma, with thoracoscopic thymectomy (TT) being increasingly performed. This present review article aimed to summarize current studies comparing TT and open thymectomy (OT). Recently, most patients with Masaoka stage I–II thymoma have been receiving TT. This procedure is associated with a significantly shorter post-operative hospital stay, decreased intraoperative blood loss, and fewer complications compared with OT. Recurrence rates of thymoma after TT range from 0% to 6.7%, and the 5-year disease-free survival (DFS) ranges from 83.3% to 96%. The oncological outcomes of TT are comparable to that of OT. Masaoka stage and the World Health Organization (WHO) type classification are valuable predictors of the prognosis of thymoma; hence, the optimal treatment for thymoma should be performed according to these two. TT is less invasive, with equivalent oncological outcomes, when compared with the OT. Minimally invasive surgery including TT for stage I–II thymomas is becoming the mainstay of therapy.
- 11 April 2017
- Published by AME Publishing Company in Journal of Visualized Surgery
- Vol. 3 (4) , 54
Surgical and oncological outcomes of thoracoscopic thymectomy for thymoma
Thymoma remains the most common primary anterior mediastinal neoplasm. Surgical resection remains central to the treatment of thymoma, with thoracoscopic thymectomy (TT) being increasingly performed. This present review article aimed to summarize current studies comparing TT and open thymectomy (OT). Recently, most patients with Masaoka stage I–II thymoma have been receiving TT. This procedure is associated with a significantly shorter post-operative hospital stay, decreased intraoperative blood loss, and fewer complications compared with OT. Recurrence rates of thymoma after TT range from 0% to 6.7%, and the 5-year disease-free survival (DFS) ranges from 83.3% to 96%. The oncological outcomes of TT are comparable to that of OT. Masaoka stage and the World Health Organization (WHO) type classification are valuable predictors of the prognosis of thymoma; hence, the optimal treatment for thymoma should be performed according to these two. TT is less invasive, with equivalent oncological outcomes, when compared with the OT. Minimally invasive surgery including TT for stage I–II thymomas is becoming the mainstay of therapy.
- 1 April 2017
- Published by AME Publishing Company in ASVIDE
- Vol. 4 (1) , 147
Thoracoscopic subtotal thymectomy (STT) for thymoma. In this case, STT from left thoracic cavity for a large thymoma
- 1 April 2017
- Published by AME Publishing Company in ASVIDE
- Vol. 4 (1) , 147
Thoracoscopic subtotal thymectomy (STT) for thymoma. In this case, STT from left thoracic cavity for a large thymoma
- Open Access
- 23 March 2017
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 25 (1) , 103-108
Thoracoscopic thymectomy is a feasible and less invasive alternative for the surgical treatment of large thymomas
OBJECTIVES: Thoracoscopic surgery is widely used for the surgical treatment of thymoma. However, large-sized thymomas are typically treated using open surgery. This study evaluated the feasibility of performing thoracoscopic thymectomy (TT) for thymoma ≥50 mm. METHODS: A retrospective review was conducted on 135 patients who underwent TT or open thymectomy (OT) for Masaoka stage I–IVa thymoma between 1996 and 2014. RESULTS: Patients were first divided into two groups based on thymoma size: thymoma ≥50 mm and thymoma P = 0.5352). Patients in the thymoma ≥50 mm group were further subdivided into TT and OT groups. The length of postoperative hospital stay was significantly shorter in the TT group than in the OT group (5 vs 14 days, P < 0.0001), with significantly fewer postoperative complications (6 patients vs 14 patients, P = 0.0008). There was no significant difference in the 5-year DFS between patients with thymoma ≥50 mm in the TT and OT groups (P = 0.3501). Finally, patients undergoing TT were further subdivided into thymoma ≥50 mm and thymoma P = 0.6661). Masaoka stages III–IV, but not thymoma size, were an independent prognostic factor for DFS. CONCLUSIONS: These results demonstrate the decreased invasiveness and feasibility of TT for large-sized thymomas.
- 23 March 2017
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 25 (1) , 103-108
Open AccessThoracoscopic thymectomy is a feasible and less invasive alternative for the surgical treatment of large thymomas
OBJECTIVES: Thoracoscopic surgery is widely used for the surgical treatment of thymoma. However, large-sized thymomas are typically treated using open surgery. This study evaluated the feasibility of performing thoracoscopic thymectomy (TT) for thymoma ≥50 mm. METHODS: A retrospective review was conducted on 135 patients who underwent TT or open thymectomy (OT) for Masaoka stage I–IVa thymoma between 1996 and 2014. RESULTS: Patients were first divided into two groups based on thymoma size: thymoma ≥50 mm and thymoma P = 0.5352). Patients in the thymoma ≥50 mm group were further subdivided into TT and OT groups. The length of postoperative hospital stay was significantly shorter in the TT group than in the OT group (5 vs 14 days, P < 0.0001), with significantly fewer postoperative complications (6 patients vs 14 patients, P = 0.0008). There was no significant difference in the 5-year DFS between patients with thymoma ≥50 mm in the TT and OT groups (P = 0.3501). Finally, patients undergoing TT were further subdivided into thymoma ≥50 mm and thymoma P = 0.6661). Masaoka stages III–IV, but not thymoma size, were an independent prognostic factor for DFS. CONCLUSIONS: These results demonstrate the decreased invasiveness and feasibility of TT for large-sized thymomas.
- Open Access
- 30 August 2016
- Published by Springer Nature in Respiratory Research
- Vol. 17 (1) , 1-12
Metformin attenuates lung fibrosis development via NOX4 suppression
Accumulation of profibrotic myofibroblasts in fibroblastic foci (FF) is a crucial process for development of fibrosis during idiopathic pulmonary fibrosis (IPF) pathogenesis, and transforming growth factor (TGF)-β plays a key regulatory role in myofibroblast differentiation. Reactive oxygen species (ROS) has been proposed to be involved in the mechanism for TGF-β-induced myofibroblast differentiation. Metformin is a biguanide antidiabetic medication and its pharmacological action is mediated through the activation of AMP-activated protein kinase (AMPK), which regulates not only energy homeostasis but also stress responses, including ROS. Therefore, we sought to investigate the inhibitory role of metformin in lung fibrosis development via modulating TGF-β signaling. TGF-β-induced myofibroblast differentiation in lung fibroblasts (LF) was used for in vitro models. The anti-fibrotic role of metfromin was examined in a bleomycin (BLM)-induced lung fibrosis model. We found that TGF-β-induced myofibroblast differentiation was clearly inhibited by metformin treatment in LF. Metformin-mediated activation of AMPK was responsible for inhibiting TGF-β-induced NOX4 expression. NOX4 knockdown and N-acetylcysteine (NAC) treatment illustrated that NOX4-derived ROS generation was critical for TGF-β-induced SMAD phosphorylation and myofibroblast differentiation. BLM treatment induced development of lung fibrosis with concomitantly enhanced NOX4 expression and SMAD phosphorylation, which was efficiently inhibited by metformin. Increased NOX4 expression levels were also observed in FF of IPF lungs and LF isolated from IPF patients. These findings suggest that metformin can be a promising anti-fibrotic modality of treatment for IPF affected by TGF-β.
- 30 August 2016
- Published by Springer Nature in Respiratory Research
- Vol. 17 (1) , 1-12
Open AccessMetformin attenuates lung fibrosis development via NOX4 suppression
Accumulation of profibrotic myofibroblasts in fibroblastic foci (FF) is a crucial process for development of fibrosis during idiopathic pulmonary fibrosis (IPF) pathogenesis, and transforming growth factor (TGF)-β plays a key regulatory role in myofibroblast differentiation. Reactive oxygen species (ROS) has been proposed to be involved in the mechanism for TGF-β-induced myofibroblast differentiation. Metformin is a biguanide antidiabetic medication and its pharmacological action is mediated through the activation of AMP-activated protein kinase (AMPK), which regulates not only energy homeostasis but also stress responses, including ROS. Therefore, we sought to investigate the inhibitory role of metformin in lung fibrosis development via modulating TGF-β signaling. TGF-β-induced myofibroblast differentiation in lung fibroblasts (LF) was used for in vitro models. The anti-fibrotic role of metfromin was examined in a bleomycin (BLM)-induced lung fibrosis model. We found that TGF-β-induced myofibroblast differentiation was clearly inhibited by metformin treatment in LF. Metformin-mediated activation of AMPK was responsible for inhibiting TGF-β-induced NOX4 expression. NOX4 knockdown and N-acetylcysteine (NAC) treatment illustrated that NOX4-derived ROS generation was critical for TGF-β-induced SMAD phosphorylation and myofibroblast differentiation. BLM treatment induced development of lung fibrosis with concomitantly enhanced NOX4 expression and SMAD phosphorylation, which was efficiently inhibited by metformin. Increased NOX4 expression levels were also observed in FF of IPF lungs and LF isolated from IPF patients. These findings suggest that metformin can be a promising anti-fibrotic modality of treatment for IPF affected by TGF-β.